Taken together, these findings suggest that the genetically proxied association between PCSK9 inhibition and a lower risk of prostate cancer is unlikely to be due to a mechanism involving the lowering of LDL-c levels. This evidence concerns the gene PCSK9 and prostate carcinoma.